Clopidogrel hyper-response and bleeding risk in neurointerventional procedures (Q43652213)

25 November 2017

Clopidogrel hyper-response and bleeding risk in neurointerventional procedures (English)

1 reference

25 November 2017

1 reference

5

1 reference

25 November 2017

C Goh

1

1 reference

25 November 2017

L Churilov

series ordinal

2

1 reference

25 November 2017

P Mitchell

series ordinal

3

1 reference

25 November 2017

R Dowling

series ordinal

4

1 reference

25 November 2017

language of work or name

1 reference

28 December 2012

1 reference

American Journal of Neuroradiology

25 November 2017

1 reference

25 November 2017

34

1 reference

25 November 2017

4

1 reference

25 November 2017

721-726

1 reference

Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond

25 November 2017

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Resistance to aspirin and clopidogrel therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogr

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A3418

21 January 2018

Identifiers

DOI

10.3174/AJNR.A3418

1 reference

25 November 2017

1 reference